company background image
DSRL.F logo

DiaSorin OTCPK:DSRL.F Stock Report

Last Price

US$92.22

Market Cap

US$5.1b

7D

0%

1Y

n/a

Updated

27 Mar, 2024

Data

Company Financials +

DSRL.F Stock Overview

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China.

DSRL.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance2/6
Financial Health3/6
Dividends4/6

DiaSorin S.p.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DiaSorin
Historical stock prices
Current Share Price€92.22
52 Week High€120.00
52 Week Low€86.00
Beta0.15
1 Month Change0%
3 Month Change-7.58%
1 Year Changen/a
3 Year Change-44.62%
5 Year Change-7.87%
Change since IPO393.16%

Recent News & Updates

Recent updates

Shareholder Returns

DSRL.FUS Medical EquipmentUS Market
7D0%-0.2%0.6%
1Yn/a12.0%29.5%

Return vs Industry: Insufficient data to determine how DSRL.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how DSRL.F performed against the US Market.

Price Volatility

Is DSRL.F's price volatile compared to industry and market?
DSRL.F volatility
DSRL.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: DSRL.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DSRL.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19683,278Carlo Rosahttps://diasoringroup.com/en

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System.

DiaSorin S.p.A. Fundamentals Summary

How do DiaSorin's earnings and revenue compare to its market cap?
DSRL.F fundamental statistics
Market capUS$5.06b
Earnings (TTM)US$172.13m
Revenue (TTM)US$1.24b

29.4x

P/E Ratio

4.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DSRL.F income statement (TTM)
Revenue€1.15b
Cost of Revenue€407.00m
Gross Profit€741.00m
Other Expenses€582.00m
Earnings€159.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 10, 2024

Earnings per share (EPS)2.98
Gross Margin64.55%
Net Profit Margin13.85%
Debt/Equity Ratio68.7%

How did DSRL.F perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

34%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.